Philip Breitfeld, MD

Chief Strategy & Innovation Officer

Philip Breitfeld, MD, serves as the Chief Strategy & Innovation Officer at Champions Oncology.  Dr. Breitfeld has more than 30 years of experience in oncology and was most recently Global Vice President at IQVIA, responsible for the Therapeutic Centers of Excellence. Prior to that, he led the Oncology Center of Excellence at IQVIA where he worked with many large, mid-size and emerging biopharmaceutical firms. He held senior clinical development positions at Merck KGaA (EMD Serono in the US), where he led oncology development in the US, and at BioCryst, where he led oncology development and was Associate Chief Medical Officer.

Prior to his career in industry, he held academic positions at Harvard, University of Massachusetts, Indiana University, and Duke. He has approximately 50 publications in the literature dealing with basic cell and molecular biology, and translational and clinical oncology. He was trained in Pediatric Hematology/Oncology at the Dana-Farber Cancer Institute, was a visiting scientist at the Whitehead Institute at MIT, received his medical degree (MD) from the University of Rochester, and his undergraduate degree (AB in chemistry) from Princeton. Dr. Breitfeld is also a Director on the Company’s Board of Directors.